Clinical Collection on Rheumatic Diseases

This program consists of three e-learning lessons designed to provide clinicians with the latest advancements in research on rheumatic diseases.

In this edition, we aim for rheumatologists participating in the course to:

• Understand how collaboration between dermatologists and rheumatologists can improve the management of psoriatic arthritis and persistent psoriasis.
• Recognize that certain biomarkers may not directly influence drug efficacy but could serve as passive indicators or play more complex roles that warrant further investigation.
• Explore two emerging concepts in rheumatology: prevention and therapeutic interception, alongside the need for stronger methodological approaches to achieve personalized prevention strategies.

In summary, novel topics and approaches that will give rheumatologists food for thought.

Participants who complete the course will be eligible for Continuing Medical Education (CME) credits recognized by the Spanish National Health System (available exclusively for practicing physicians in Spain).

Dates: 21/10/2024 – 31/05/2025
1.2 credits (8 teaching hours)
Registration number: 09/038258-MD

V1 N5: Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events (2h. teaching hours)

V1 N6: Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis (2h. teaching hours)

V1 N7: Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis (2h. teaching hours)

V1 N8: Polygenic risk score: the potential role in the management of systemic lupus erythematosus (2h. teaching hours)

Dates: 01/07/2025 – 12/30/2025
0.9 credits (6h teaching hours)
Registration number: 09/038919-MD

V1 N9: Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series (2h. teaching hours)

V1 N10: Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial (2h. teaching hours)

V1 N11: Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease (2h. teaching hours)